Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia

Published:2023-06-22 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Yin Lingling¹²³,Xu Jiawen²³,Wu Wenjian⁴,Niu Mingshan¹²³,Li Zhenyu¹²³,Zhu Feng¹²³,Xu Kailin¹²³

Affiliation:

1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China

2. Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China

3. Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of China

4. Medical Record and Statistical Office, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China

Funder

the National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2224625

Reference33 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

2. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review

3. STAT3 and STAT5 Activation in Solid Cancers

4. Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia

5. Pharmacologic inhibition of STAT5 in acute myeloid leukemia

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP